METX Stock Chart & Stats
C$2.50
C$0.05(1.25%)
At close: 4:00 PM EST
C$2.50
C$0.05(1.25%)
Day’s Range― - ―
52-Week RangeC$0.79 - C$8.00
Previous CloseN/A
Volume600.00
Average Volume (3M)254.00
Market Cap
C$59.80M
Enterprise ValueC$117.03M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding30,049,494
10 Day Avg. Volume10
30 Day Avg. Volume254
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ME Therapeutics Holdings, Inc. News
METX FAQ
What was ME Therapeutics Holdings, Inc.’s price range in the past 12 months?
ME Therapeutics Holdings, Inc. lowest stock price was C$0.79 and its highest was C$8.00 in the past 12 months.
What is ME Therapeutics Holdings, Inc.’s market cap?
ME Therapeutics Holdings, Inc.’s market cap is C$59.80M.
When is ME Therapeutics Holdings, Inc.’s upcoming earnings report date?
ME Therapeutics Holdings, Inc.’s upcoming earnings report date is Dec 02, 2026 which is in 144 days.
How were ME Therapeutics Holdings, Inc.’s earnings last quarter?
ME Therapeutics Holdings, Inc. released its earnings results on Jun 26, 2026. The company reported -C$0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.013.
Is ME Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts ME Therapeutics Holdings, Inc.’s price is currently Overvalued.
Does ME Therapeutics Holdings, Inc. pay dividends?
ME Therapeutics Holdings, Inc. does not currently pay dividends.
What is ME Therapeutics Holdings, Inc.’s EPS estimate?
ME Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ME Therapeutics Holdings, Inc. have?
ME Therapeutics Holdings, Inc. has 30,049,494 shares outstanding.
What happened to ME Therapeutics Holdings, Inc.’s price movement after its last earnings report?
ME Therapeutics Holdings, Inc. reported an EPS of -C$0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ME Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:METX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ME Therapeutics Holdings, Inc.
ME Therapeutics is a pre-clinical biopharmaceutical company dedicated to the discovery and development of novel cancer immunotherapies. Using our combined expertise in tumour immunology, T cell biology and myeloid cell development, we are developing biological and small molecule drugs to target novel pathways involved in cancer-induced immune suppression. Our therapies have the potential to work on their own and in combination with other cancer immunotherapies across several cancer types.
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
Defence Therapeutics
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---